Background-Acute cardiac contractile dysfunction is common after cardiopulmonary bypass (CPB). A potential molecular mechanism is enhanced ␤-adrenergic receptor kinase (␤ARK1) activity, because ␤-adrenergic receptor (␤AR) signaling is altered in cardiomyocytes after cardioplegia. Therefore, we examined whether adenovirus-mediated intracoronary delivery of a ␤ARK1 inhibitor (Adv-␤ARKct) could prevent post-CPB dysfunction. Methods and Results-Rabbits were randomized to receive 5ϫ10
Ventricular Dysfunction After Cardioplegic Arrest Is
Improved After Myocardial Gene Transfer of a ␤-Adrenergic Receptor Kinase Inhibitor C old cardioplegic cardiac arrest, either during cardiopulmonary bypass (CPB) procedures or during harvest and transport of a donor heart for transplantation, induces a degree of cardiac dysfunction by the time the heart is reperfused. Left ventricular (LV) compliance as well as LV contractility and relaxation are often impaired, which necessitates the use of inotropic agents for postoperative hemodynamic support. 1 At a molecular level, the myocardial ␤-adrenergic receptor (␤AR) signaling system is crippled during the cold ischemic period and is not immediately restored by warm blood reperfusion. [2] [3] [4] [5] [6] Importantly, cardiac ␤ARs are the most powerful means to support myocardial contractile function, and thus, the inotropic reserve of postsurgery hearts is lost.
Both ␤ 1 -and ␤ 2 -ARs are desensitized during CPB, which might be a direct result of a large local release of catecholamines. [2] [3] [4] In addition, although total ␤AR density does not change in human atrial samples taken before, during, or after CPB, ␤-agonist-stimulated adenylyl cyclase activity is decreased, suggesting an important role for ␤AR uncoupling. [2] [3] [4] [5] [6] The ␤-adrenergic receptor kinase (␤ARK1 or GRK2), a member of the G protein-coupled receptor kinase family (GRK), is responsible for phosphorylating and uncoupling agonist-occupied ␤ARs. 7 Interestingly, ␤ARK1 expression and activity are increased in different forms of heart disease, including heart failure 8 and myocardial ischemia. 9 Consistent with this is the finding that cardiac ␤ARK1 expression can also be increased after acute catecholamine exposure. 10 Thus, ␤ARK1 may be the key molecule in initiating ␤AR uncoupling early after cardioplegic arrest.
␤ARK1 activity has been shown to be elevated in models of ischemia-reperfusion, 9 ,11 and we recently demonstrated that myocardial recovery after ischemia-reperfusion injury is significantly impaired in transgenic mice overexpressing ␤ARK1. 12 Although cold cardioplegic solutions are supposed to protect the heart, some similarities may exist between ischemia-reperfusion and cardioplegic cardiac arrest followed by warm blood reperfusion. Accordingly, we hypothesized that inhibition of ␤ARK1 may represent a new strategy to prevent myocardial dysfunction after reperfusion of cardioplegia-arrested hearts. We previously developed a peptide that inhibits ␤ARK1 activity (␤ARKct). [13] [14] [15] The ␤ARKct is a 194-amino-acid peptide corresponding to the carboxyl terminus end of ␤ARK1, and it includes the sequence responsible for binding to the ␤␥-subunit of activated heterotrimeric G proteins (G␤␥), a process required for ␤ARK1 activity. [13] [14] [15] In the present study, we demonstrate that intracoronary adenovirus-mediated gene transfer of the ␤ARKct (Adv-␤ARKct) before cardioplegic arrest prevents LV dysfunction by the time the heart is reperfused.
Methods

Adenoviral Constructs
The adenoviral backbone for Adv-␤ARKct is a second-generation replication-deficient serotype 2 adenovirus with deletions of the E1 and E4 (except for ORF6), as previously described. 16, 17 Aliquots of 5ϫ10 11 total viral particles (TVP) were thawed and mixed in PBS for a final volume of 2 mL immediately before intracoronary delivery.
In Vivo Intracoronary Gene Delivery
Adult male New Zealand White rabbits (3 kg) were operated on as previously described. 17, 18 Procedures were humanely performed in accordance with the regulations adopted by the National Institutes of Health and approved by the Animal Care and Use Committee of Duke University. To control for ␤ARKct expression, a group of animals randomly received 2 mL of PBS by use of the same delivery technique.
Isolated Heart Preparation and LV Function Assessment
Five days after delivery of either the transgene or PBS, animals were reanesthetized and mechanically ventilated. A clamshell thoracic incision was performed before 3000 IU of heparin was injected intravenously. The inferior vena cava was transected, and animals were partially exsanguinated to unload the LV before the aorta was cross-clamped and 30 mL of University of Wisconsin cardioplegic solution was injected into the LV cavity, allowing cardiac arrest within 5 seconds. The great vessels, pulmonary veins, and superior vena cava were transected, and the heart was transferred into 0.9% saline solution at 4°C. After 15 minutes or 4 hours, hearts were hung on a modified Langendorff apparatus and perfused as previously described. 19, 20 An LV latex balloon was positioned and connected to a pressure transducer (Millar Instruments), and its volume was adjusted to assess a baseline condition of 0 mm Hg end-diastolic pressure (LVEDP). After 30 minutes of reperfusion, baseline LV pressures, responses to standard increases of end-diastolic volume (LVEDV), and responses to standard doses of isoproterenol (Iso) were recorded. After termination of functional measurements, hearts were kept perfused for 30 minutes before samples of the ventricles were frozen in liquid nitrogen for biochemical analysis. A control group included hearts isolated from rabbits that had not undergone surgery, quickly harvested without being arrested, and immediately reperfused on the Langendorff apparatus.
Myocardial ␤AR Density and Signaling
Membranes were prepared as previously described. 15, 17, 21 Total ␤AR density was determined by radioligand binding with a saturating concentration (300 pmol/L) of 125 I-labeled cyanopindolol at 37°C for 1 hour as described. 17 For adenylyl cyclase activity, 20 g of myocardial membrane protein was incubated with 0.1 mol/L [␣-
32 P]ATP for 15 minutes at 37°C under basal conditions or in the presence of 1 mmol/L Iso or 10 mmol/L sodium fluoride (NaF). cAMP production was quantified by standard methods described previously. 15, 17 GRK activity assay was assessed in cytosolic or membrane fractions with rhodopsin-enriched rod outer segment membranes as we have previously described. 10 ␤ARK1 levels were visualized by Western blotting as previously described. 10 
Northern Analysis
Total RNA was isolated from frozen LV samples, and Northern blot analysis was performed by standard methods as previously described. 17 
Statistical Analysis
Data are expressed as meanϮSEM. Student's t test was used for comparison between groups, whereas comparison of Iso doseresponse or LVEDV response were done by 2-way ANOVA. For all tests, a value of PϽ0.05 was considered significant.
Results
LV Physiology After Cardioplegia
To examine the effect of ␤ARK1 inhibition on postcardioplegic LV dysfunction, we delivered either the ␤ARKct transgene (Adv-␤ARKct) or PBS into normal rabbit hearts by use of an intracoronary in vivo delivery technique we recently developed. 18 Transgene expression was confirmed by Northern blot analysis 5 days after delivery of 5ϫ10 11 TVP of Adv-␤ARKct (nϭ9) (Figure 1 ). LV contractility (LV dP/ dt max ), LV relaxation (LV dP/dt min ), and LVEDP were all progressively altered by prolonged cardioplegic arrest in hearts that received only PBS compared with nonarrested hearts (Table and Figure 2 ). In particular, the response to Iso was significantly decreased after 4 hours of cardioplegic arrest compared with control nonarrested hearts ( Figure 2C and 2D). LV contractility and relaxation in hearts treated with Adv-␤ARKct 5 days before surgery, however, were both significantly increased during the reperfusion period after a 15-minute cardioplegic arrest compared with PBS-treated arrested hearts (Figure 2A and 2B). LV function was also improved after 4 hours of cardioplegic arrest in hearts that received intracoronary Adv-␤ARKct delivery 5 days earlier as opposed to hearts that received PBS only ( Figure 2C and 2D). In fact, in the more immediate cardioplegic setting (15 minutes), ␤ARKct expression even enhanced the LV function of hearts significantly above that of the nonarrested control hearts (Figure 2A and 2B). Interestingly, in Adv-␤ARKct-treated hearts after 4 hours of cold cardioplegia, LV function was still comparable to that of normal nonarrested hearts ( Figure 2C and 2D ). In addition, LV compliance, as measured by LVEDP variation with increasing preload, was significantly impaired after 4 hours of cardioplegic arrest. This parameter of LV function, however, was also restored with ␤ARKct expression, because LVEDP remained in the normal range for hearts previously treated with Adv-␤ARKct ( Figure 3 ). Increased heart rate can sometimes occur after cardiac insult and thus be a sign of cardiac dysfunction. We found significantly increased heart rate at 4 hours after CPB (Figure 4) . Importantly, all groups that had previously been treated with intracoronary ␤ARKct had normal heart rates compared with control nonarrested hearts (Figure 4 ).
␤AR Signaling After Cardioplegic Arrest
We analyzed biochemical ␤AR signaling in myocardium after reperfusion of arrested hearts. This was done 30 minutes after termination of functional measurements to allow washout of residual Iso. After 15 minutes of cardioplegic expo- Baseline condition corresponds to the LVEDV that gives an LVEDP of 0 mm Hg, which was used to standardize LVEDV at the initiation of each experiment. *PϽ0.01, †PϽ0.001, ‡PϽ0.05 vs control (2-way ANOVA). 
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sure, myocardial ␤AR density was already decreased in LV membranes prepared from hearts that received PBS 5 days earlier ( Figure 5A ). A similar loss of ␤AR density was also evident in hearts arrested for 4 hours ( Figure 5A ). Hearts that received Adv-␤ARKct 5 days previously, however, had significantly higher ␤AR density at either 15 minutes or 4 hours, and these values were in the normal range compared with control hearts not exposed to cardioplegia ( Figure 5A ). These acute changes in ␤AR density may reflect internalization, and that may include hyperactive desensitization mechanisms. Therefore, we measured ␤ARK1 (GRK2) levels and activity. We have previously shown that cytosolic myocardial GRK activity is almost exclusively a result of ␤ARK1. 22 We found GRK activity to be significantly increased after 4 hours of cardioplegia in hearts previously treated with PBS ( Figure 5B ). GRK activity, however, was unaltered even after prolonged cardioplegic arrest in hearts treated with Adv-␤ARKct ( Figure 5B ). Because active ␤ARK1 resides in the membrane fraction of intact cells after G␤␥-dependent translocation, however, we also examined the levels of membrane ␤ARK1 by immunoblotting. ␤ARK1 levels were elevated in membranes from PBS-treated arrested hearts ( Figure 5C ). In contrast, less ␤ARK1 was found in the membrane of ␤ARKct-expressing hearts in both the short and long term ( Figure 5C ).
We also examined ␤AR signaling in these hearts. Basal and Iso-stimulated adenylyl cyclase activity were decreased after 15 minutes of cold cardioplegic arrest compared with normal nonarrested hearts, whereas they remained unchanged in Adv-␤ARKct hearts ( Figure 5D ). NaF-stimulated adenylyl cyclase activity was unchanged at 15 minutes but decreased after 4 hours of cardioplegic exposure ( Figure 5D ). This may indicate postreceptor defects after cardiac arrest. Interestingly, in LV membrane prepared from hearts that received Adv-␤ARKct 5 days earlier, NaF-stimulated adenylyl cyclase activity was unchanged at both 15 minutes and 4 hours ( Figure 5D ). Thus, ␤ARKct expression was capable of restoring the myocardial ␤AR signaling system in cardioplegia-arrested hearts.
Discussion
Inhibition of ␤ARK1 activity by adenovirus-mediated gene transfer of the ␤ARKct 5 days before a cold cardioplegic cardiac arrest prevents myocardial dysfunction when the heart is reperfused. Compared with normal nonarrested hearts, LV function in ␤ARKct-expressing hearts is improved after a short cold ischemic period, and although function progressively decreases with prolonged cardiac arrest, ␤ARKct expression maintains function within normal limits and delays development of the functional consequences of cardioplegic injury. Previous studies examining biochemical abnormalities of cold cardioplegia or warm blood reperfusion suggested that defects in ␤AR signaling were associated with this treatment. [2] [3] [4] [5] [6] Notably, early changes in ␤AR coupling with its effector adenylyl cyclase occur, similar to what is observed during evolution of chronic cardiac failure. [2] [3] [4] [5] Our present results demonstrate that gene transfer of a ␤ARK1 inhibitor peptide prevents alterations in ␤AR signaling and therefore confirm a role of ␤ARK1 in altering ventricular function after cardioplegic arrest.
We have previously demonstrated the positive effect of ␤ARKct overexpression on myocardial function in vivo in transgenic mice 15, 23, 24 or ex vivo in transplantation studies in which transgenes were delivered immediately after graft harvest and before transplantation of the graft into the recipient animal. 20 In addition, we recently delivered Adv␤ARKct in rabbits simultaneously with the creation of an LV myocardial infarction and observed improved LV function compared with animals that received an empty virus or PBS only. 17 In this study, ␤AR signaling remained normal in animals treated with the ␤ARK inhibitor transgene, whereas it was dramatically impaired in nontreated animals, with a reduction in ␤AR density, a decrease in adenylyl cyclase activity in response to Iso stimulation, and increased expression and activity of ␤ARK1. 17 In fact, the development of Figure 3 . LV compliance as measured by LVEDP in response to increasing LVEDV was measured in hearts exposed to cardioplegic solution and arrested for 4 hours before being reperfused on a Langendorff apparatus. Measures were taken 5 days after intracoronary delivery of either 5ϫ10
11 TVP Adv-␤ARKct (᭛, nϭ4) or PBS (▫, nϭ4). Nonarrested control hearts were directly hung and perfused on Langendorff apparatus (', nϭ4). Basal LVEDV was standardized by adjusting intraventricular balloon volume to an LVEDP of 0 mm Hg (basal). *PϽ0.05 (PBS vs Adv-␤ARKct). †PϽ0.05 (PBS vs control). ‡PϭNS (␤ARKct vs control). 
Circulation October 23, 2001
heart failure that initially is associated with myocardial infarction in this model was significantly delayed in the presence of the ␤ARKct transgene, demonstrating that ␤ARK1 is critically involved in the pathogenesis of ischemic cardiomyopathy. 17 The design of our present study offers insight into the acute functional and biochemical changes that occur during the reperfusion period after cardioplegic arrest. Modifications of ␤AR signaling were dependent on the exposure time to cardioplegic solution in previously untreated (PBS) animals, whereas no significant changes were observed in animals that were pretreated with Adv-␤ARKct. This effect was seen in hearts exposed short-term or for as long as 4 hours. The immediate loss in ␤AR density, which persisted after prolonged exposure to cardioplegic solution, was abolished in hearts expressing the ␤ARKct. In fact, ␤AR density was significantly higher than control counterparts in right ventricles of ␤ARKct-treated hearts, whereas it was unchanged in PBS-treated hearts (data not shown). This suggests that downregulation as opposed to desensitization of ␤ARs is probably not a critical event in the sequence of cardioprotective adaptive mechanisms. The observation that chronic ␤AR antagonist administration in patients before CPB with cardioplegic arrest did not prevent acute desensitization supports this hypothesis. 3, 4 With respect to desensitization, we found increased activated ␤ARK1 levels in arrested hearts. Importantly, in the ␤ARKct-treated hearts, less ␤ARK1 appeared to be actively translocated from the cytosol to the membrane after cardioplegia and reperfusion. Thus, it appears that ␤ARK1 plays a critical role in the ␤AR changes associated with cardioplegic arrest and thus acts as the primary target for ␤ARKct action. Therefore, dynamic changes that occur progressively during cold myocardial ischemia certainly explain, at least partially, the progressive degradation in LV function with prolonged cardioplegic cardiac arrest. Adenovirus-mediated gene transfer of ␤ARKct appears to stabilize ␤AR signaling during cardioplegia and reperfusion and consequently improves LV contractility and relaxation, as well as LV compliance and heart rate. Adenylyl cyclase activity in response to ␤-agonist stimulation is clearly affected by cold cardioplegic exposure, as demonstrated by animal studies 2 as well as results obtained from human right atrial samples taken during CPB procedures. [3] [4] [5] [6] Few studies have analyzed the adenylyl cyclase activity in response to NaF stimulation, and results are controversial. Some studies show no changes in direct G protein-stimulated adenylyl cyclase activity, 5 whereas others demonstrate a decreased activity in animals 6 or in human samples. 3 Our results demonstrate a time-dependent variation in NaF-stimulated adenylyl cyclase activity. Although Iso-stimulated adenylyl cyclase activity was already decreased after a short period of cardioplegic arrest, direct adenylyl cyclase stimulation via G proteins (NaF) showed normal activity after 15 minutes of cardioplegia, whereas it was significantly decreased after prolonged exposure to cardioplegia. Thus, with prolonged cardiac arrest, there were both receptor and postreceptor defects in this system. Gene transfer of ␤ARKct before cardioplegic cardiac arrest, however, preserved the adenylyl cyclase pathway at all levels. This is probably due to the overall improved function before cardioplegic arrest.
As opposed to progressive modifications in ␤AR signaling during development of chronic heart failure, CPB represents a clinically relevant situation in which early alterations in ␤AR signaling take place as a consequence of changes in the extracellular milieu during both the cardioplegia and reperfusion periods. Cold cardioplegic solutions are used daily, not only for preservation of a donor heart during harvesting and transport but also primarily for myocardial protection during CPB and cardiac arrest. Ventricular dysfunction that occurs at the time of reperfusion prolongs any hospital stay and favors postcardiotomy morbidity. Therefore, there is a clinical need for different cardioplegic methods that not only provide myocardial protection during the cold ischemic period but also mainly ensure adequate ventricular function during reperfusion. In this regard, adenovirus-mediated gene transfer of an inhibitor of ␤ARK1 before cold cardioplegic arrest may constitute a new strategy to prevent postoperative LV dysfunction. Moreover, it is possible that small molecules could be developed to inhibit ␤ARK1 activity in a pharmacological manner, which may represent a novel therapeutic approach for acute cardiac dysfunction.
